News Detail
Another hit for Roche UnitedHealthcare backs Amgen biosims over blockbuster oncology meds
Two of Roches oncology blockbusters are facing dire straits as first-ever biosimilar competitors have entered the U.S. market. Now, a major insurer is putting its money on the new guys.
Chemxpert Demo Video
Dataset Sample
Chemical Name |
Synonyms |
Molecular Formula |
Molecular Weight |
|---|
Dataset Sample
| Product Name | Innovator |
|---|
Dataset Sample
| Product Name | Market Status |
|---|
Dataset Sample
| Product Name | Indication |
|---|
Dataset Sample
| Product Name | Therapeutic Segment |
|---|
Thank you for your enquiry
Your product will be updated soon in our database